Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Nov 29, 2023
Dr. Jim Woody, CEO and Director of 180 Life Sciences, discusses the company's vision for safer pain and inflammation management. Their earlier work on anti-TNF therapy revolutionized the treatment of conditions such as rheumatoid arthritis. Now 180 Life Sciences focuses on additional indications of inflammation, fibrosis, and cognitive dementia for using anti-TNFs. Jim highlights their research on the anti-inflammatory and analgesic properties of cannabinoids and the potential of synthetic cannabinoid analogs for pain management and appetite suppression.
Jim elaborates, "Many years ago, I was Chief Scientific Officer at a company called Centocore, and they were one of the first companies developing therapeutic monoclonal antibodies. One of them that we developed was called anti-TNF. It was Infliximab, which was the FDA name that it received. In your body, circulating around, there are hundreds of small proteins. Those that modify the immune system are called cytokines, and most of them are good actors. One of the bad actors is what they call tumor necrosis factor. It was given that name because of some mouse studies in cancer that were done, although they turned out to be incorrect."
"My colleagues in the UK, Dr. Marc Feldmann and Dr. Ravinder Maini had data suggesting that rheumatoid arthritis inflammation and pain were driven by TNF. We were the first to treat ten patients with anti-TNF in this program, in the whole world. Now, anti-TNF is the therapy of choice for rheumatoid arthritis, which, of course, is severe inflammation of the joints."
"We also found out that TNF was driving these inflammations in Crohn's disease, Psoriasis, and in Ulcerative Colitis. We discovered all of those from Centocore, and now anti-TNF is the largest-selling class of biologics, at almost $40 billion a year. The current favorite is Humira from AbbVie, but J&J, who bought Centocore, still makes a billion dollars a year from Infliximab sales or its brand name Remicade."
#180LifeSciences #LifeSciences #CBD #Biotech #Fibrosis #AntiTNF #DupuytrensDisease #PainManagement #Inflammation
